Australija - engleski - Department of Health (Therapeutic Goods Administration)

rbk nutraceuticals pty ltd - colecalciferol,calcium carbonate,heavy magnesium oxide -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Kanada - engleski - Health Canada

les aliments nutri-source inc. - calcium; magnesium oxide; vitamin d2; zinc gluconate - tablet - 335mg; 167mg; 135unit; 10mg - calcium 335mg; magnesium oxide 167mg; vitamin d2 135unit; zinc gluconate 10mg - vitamins & minerals

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 2 ug in 1 ml - doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. doxercalciferol injection should not be given to patients with a tendency towards hypercalcemia or current evidence of vitamin d toxicity. doxercalciferol injection is contraindicated in patients with previous hypersensitivity to doxercalciferol or any of its ingredients (see warnings and adverse reactions ).

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

sandoz inc - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 2 ug in 1 ml - doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. doxercalciferol injection should not be given to patients with a tendency towards hypercalcemia or current evidence of vitamin d toxicity. doxercalciferol injection is contraindicated in patients with previous hypersensitivity to doxercalciferol or any of its ingredients (see warnings and adverse reactions ).

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

akorn - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 4 ug in 2 ml - - doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in adult patients with ckd on dialysis. doxercalciferol is contraindicated in patients with: - hypercalcemia [see warnings and precautions (5.1)] - vitamin d toxicity [see warnings and precautions (5.1)] - known hypersensitivity to doxercalciferol or any of the inactive ingredients of doxercalciferol injection; serious hypersensitivity reactions including anaphylaxis and angioedema have been reported [see warnings and precautions (5.3), adverse reactions (6.2)]. risk summary the limited available data with doxercalciferol in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations] . in reproduction studies in rats and rabbits administered doxercalciferol during organogenesis at up to 20 mcg/kg/day and 0.1 mcg/kg/da

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 0.5 ug - doxercalciferol capsules is contraindicated in patients with: risk summary: the limited available data with doxercalciferol in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy [see clinical considerations ]. in reproduction studies in rats and rabbits administered doxercalciferol during organogenesis at up to 20 mcg/kg/day and 0.1 mcg/kg/day, respectively (approximately 25 times (rats) and less than (rabbits) the maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area), no adverse developmental effects were observed [see data ]. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - ergocalciferol; calcium lactate; calcium phosphate - oral tablet - 10microgram ; 300mg ; 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - ergocalciferol; calcium lactate; calcium phosphate - oral tablet - 10microgram ; 300mg ; 150mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

approved prescription services ltd - ergocalciferol; calcium lactate; calcium phosphate - oral tablet - 10microgram ; 300mg ; 150mg